

Icahn School of Medicine at Mount Sinai State of the School 2023



Icahn School
of Medicine at
Mount
Sinai

A Note From Dean Charney

The Icahn School of Medicine at Mount Sinai is a bold leader in scientific exploration, biomedical education, and clinical care. As we drive science forward, our eyes are always on the goal of translating our findings into new diagnostics and therapies that can improve human health. Our purpose is to expand medicine's capacity to save more lives and to improve the quality of life for patients.

A Note From Dean Charney

Our students are among the best and brightest in the nation. They receive an outstanding education here at Icahn Mount Sinai. To ensure that education remains among the best in the country we are innovating—Icahn Mount Sinai is about to introduce our new ASCEND curriculum. It emphasizes early and continuous development of clinical reasoning skills throughout our students' education.



A Note From Dean Charney


Many of our scientists have heard me say, “Don’t fear failure.” And they don’t. They are intrepid explorers, willing to take chances, because that is how we are able to meaningfully advance science and medicine and deliver discoveries that matter, discoveries that can improve the lives of our patients. Thanks to your success, our funding is growing rapidly, and we are expanding our research and clinical facilities.

At the Icahn School of Medicine at Mount Sinai, we see where science is heading. We understand the potential of new technology that can help us change the world. So, we have invested in the tools and the people who can take us into the future. We have built powerful capabilities in Artificial Intelligence, or, as I like to call it, “Augmented Intelligence”. Now we’re reaping the benefits of our strategy—and this is only the beginning of our payoff.



A Note From Dean Charney

We recruit the best and the brightest—and our brilliant scientists and clinicians are delivering stellar results. They are taking on the biggest challenges, the toughest diseases, like complex cancers and degenerative brain disease—and they're making impressive progress.



A Note From Dean Charney

Only a select few academic medical centers can do what we're doing: significantly advance science; apply research breakthroughs to develop new diagnostics and treatments; deliver the very best clinical care; and educate the next generation of great physicians, researchers, and health care leaders. Mount Sinai is doing all of this! So, as I speak with you today, I can report that the state of the Icahn School of Medicine at Mount Sinai is outstanding!

Let's review the details.



Research That Makes a Difference in the Lives of Patients

Heart



FEBRUARY 23, 2023

[Read more >](#)

Fasting negatively affects immune cells and could lead to increased risk of heart disease

Henrike Janssen; Florian Kahles; Dan Liu; Jeffrey Downey; Laura L. Koekkoek; Vladimir Roudko; Darwin D'Souza; Cameron S. McAlpine; Lennard Halle; Wolfram C. Poller; Christopher T. Chan; Shun He; John E. Mindur; Máté G. Kiss; Sumnima Singh; Atsushi Anzai; Yoshiko Iwamoto; Rainer H. Kohler; Kashish Chetal; Rustan I. Sadreyev; Ralph Weissleder; Seunghee Kim-Schulze; Miriam Merad; Matthias Nahrendorf; Filip K. Swirski

Circulation

JULY 6, 2023

[Read more >](#)

Study establishing potential of novel gene delivery vector to treat heart failure

Xisheng Li; Sabrina La Salvia; Yaxuan Liang; Marta Adamiak; Erik Kohlbrenner; Dongtak Jeong; Elena Chepurko; Delaine Ceholski; Estrella Lopez-Gordo; Seonghun Yoon; Prabhu Mathiyalagan; Neha Agarwal; Divya Jha; Shweta Lodha; George Daaboul; Anh Phan; Nikhil Raisinghani; Shihong Zhang; Lior Zangi; Edgar Gonzalez-Kozlova; Nicole Dubois; Navneet Dogra; Roger J. Hajjar; Susmita Sahoo

Cancer

nature

JULY 27, 2023

[Read more >](#)

RNA therapy combats melanoma (collaboration with Institute for Genomic Technology)

Yuebao Zhang; Xucheng Hou; Shi Du; Yonger Xue; Jingyue Yan; Diana D. Kang; Yichen Zhong; Chang Wang; Binbin Deng; David W. McComb; Yizhou Dong

nature

OCTOBER 2, 2023

[Read more >](#)

New treatment allows patients to avoid removal of bladder

Matthew D. Galsky; Siamak Daneshmand; Sudeh Izadmehr; Edgar Gonzalez-Kozlova; Kevin G. Chan; Sara Lewis; Bassam El Achka; Tanya B. Dorff; Jeremy Paul Cetnar; Brock O. Neil; Anishka D'Souza; Ronac Mamtani; Christos Kyriakopoulos; Tomi Jun; Mahalya Gogerly-Moragoda; Rachel Brody; Hui Xie; Kai Nie; Geoffrey Kelly; Amir Horowitz; Yayoi Kinoshita; Ethan Ellis; Yohei Nose; Giorgio Ioannou; Rafael Cabal; Diane M. Del Valle; G. Kenneth Haines; Li Wang; Kent W. Mouw; Robert M. Samstein; Reza Mehrazin; Nina Bhardwaj; Menggang Yu; Qianqian Zhao; Seunghee Kim-Schulze; Robert Sebra; Jun Zhu; Sacha Gnjjatic; John Sfakianos; Sumanta K. Pal

Genetics and Genomic Sciences

nature

MARCH 13, 2022

[Read more >](#)

Novel genes linked to schizophrenia are identified

Dongjing Liu; Dara Meyer; Brian Fennessy; Claudia Feng; Esther Cheng; Jessica S. Johnson; You Jeong Park; Marysia-Kolbe Rieder; Steven Ascolillo; Agathe de Pins; Amanda Dobbyn; Dannielle Lebovitch; Emily Moya; Tan-Hoang Nguyen; Lillian Wilkins; Arsalan Hassan; Psychiatric Genomics Consortium Phase 3 Targeted Sequencing of Schizophrenia Study Team; Katherine E. Burdick; Joseph D. Buxbaum; Enrico Domenici; Sophia Frangou; Annette M. Hartmann; Claudine Laurent-Levinson; Dheeraj Malhotra; Carlos N. Pato; Michele T. Pato; Kerry Ressler; Panos Roussos; Dan Rujescu...

nature

MARCH 16, 2023

[Read more >](#)

Genetic causes of three rare diseases identified

Daniel Greene; Genomics England Research Consortium; Daniela Pirri; Karen Frudd; Ege Sackey; Mohammed Al-Owain; Amaud P. J. Giese; Khushnooda Ramzan; Sehar Riaz; Itaru Yamanaka; Nele Boeckx; Chantal Thys; Bruce D. Gelb; Paul Brennan; Verity Hartill; Julie Harvengt; Tomoki Kosho; Sahar Mansour; Mitsuo Masuno; Takako Ohata; Helen Stewart; Khalid Taibah; Claire L. S. Turner; Faiqa Imtiaz; Saima Riazuddin; Takayuki Morisaki; Pia Ostergaard; Bart L. Loeys; Hiroko Morisaki; Zubair M. Ahmed; Graeme M. Birdsey; Kathleen Freson; Andrew Mumford; Ernest Turro

Brain

ScienceAdvances

OCTOBER 12, 2023

[Read more >](#)

First "multiome" atlas of brain cell development in the human cerebral cortex

Kaiyi Zhu; Jaroslav Bendl; Samir Rahman; James M. Vicari; Claire Coleman; Tereza Clarence; Ovaun Latouche; Nadejda M. Tsankova; Aiqun Li; Kristen J. Brennan; Donghoon Lee; Guocheng Yuan; John F. Fullard; Panos Roussos

nature

SEPTEMBER 20, 2023

[Read more >](#)

Biomarker that tracks recovery from treatment-resistant depression identified

Sankaraleengam Alagapan; Ki Sueng Choi; Stephen Heisig; Patricio Riva-Posse; Andrea Crowell; Vineet Tiruvadi; Mosadoluwa Obatusin; Ashan Veerakumar; Allison C. Waters; Robert E. Gross; Sinead Quinn; Lydia Denison; Matthew O'Shaughnessy; Marissa Connor; Gregory Canal; Jungho Cha; Rachel Hershenberg; Tanya Nauvel; Faical Isbaine; Muhammad Furqan Afzal; Martijn Figeet; Brian H. Kopell; Robert Butera; Helen S. Mayberg; Christopher J. Rozell

Recognized for Research Excellence




Ranked No.14 in total NIH funding among all U.S. medical schools

Source: NIH, 2023



16 basic and clinical science departments in top 20 NIH funding


Source: Blue Ridge, 2023



99th percentile among U.S. private medical schools in indirect research dollars per investigator

Source: AAMC, 2023

Our NIH Funding Is Growing: 2014–2023 (\$ in Millions)



Department Rankings for NIH Funding: Top 20

Basic Sciences

#2	#2	#3	#9	#13
Neuroscience	Genetics	Pharmacology	Microbiology	Cell Biology
\$32.6M	\$44.7M	\$21.8M	\$19.8M	\$13.8M

Clinical Sciences

#3	#4	#6	#6	#7	#11	#15	#17	#17	#20	#20
Emergency Medicine	Public Health	Physical Medicine	Psychiatry	Urology	Internal Medicine	Orthopedics	Neurosurgery	Family Medicine	Pediatrics	Radiology
\$13.3M	\$32.8M	\$2.59M	\$49.9M	\$3.44M	\$147M	\$2.96M	\$3.66M	\$1.74M	\$22.3M	\$12.6M

Source: Blue Ridge 2023 Data

Icahn Mount Sinai Is a Research Powerhouse

Mount Sinai Million Health Discovery Program

- Expanded to children and collaborations with minority institutions
- Alexander W. Charney, MD, PhD; Girish N. Nadkarni, MD, MPH

Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern

- \$16 million from NIH
- Adolfo García-Sastre, PhD; Benhur Lee, MD; Matthew Evans, PhD; Lisa Miorin, PhD; Christopher Basler, PhD; Gustavo Palacios, PhD

Allen Discovery Center for Neuroimmune Interactions

- \$10 million from Allen Institute
- Brian Kim, MD, PhD; Miriam Merad, MD, PhD; others

Innovation in Cancer Diagnostics and Treatment

- \$16 million from NIH, Multiple Myeloma Foundation, others
- Samir Parekh, MBBS; Brown Brian, PhD; Miriam Merad, MD, PhD; Keith Sigel, MD, PhD; others



What's on the Horizon: Research



Eric Nestler, MD, PhD

Dean for Academic Affairs
Chief Scientific Officer

- **AI/Machine Learning:** Placing all of Mount Sinai's clinical data into the Mount Sinai Data Ark, which will include EHR information, brain/body scans and images, digital pathology, and genomic information, allowing unprecedented ability to mine data for clinical insights
- **Clinical Trials:** Aiming to triple the number of clinical trials
- **Center for Human Disease Modeling** to drive cell systems, study disease pathophysiology, and develop novel treatments
- **Novel Therapeutics** that can turn on the immune system against tumors
 - Immune cell therapy for cancer
 - Innovative treatments for a wide range of disorders
- **Pioneering the next generation of RNA and DNA therapies**
 - New nanoparticle formulations to deliver RNAs and CRISPRs to specific organs to treat disease
 - CRISPR-based therapies for monogenic disorders such as cystic fibrosis and sickle cell anemia
 - Using RNA analogs and drug cocktails to create a cancer vaccine from a patient's tumors

Research Spaces



787 11th Avenue

- Clinical, ASC, and Research Wet Labs
- Misc. Departments



619 West 54th Street

- Center for Engineering and Precision Medicine



3 East 101st Street

April completion

- Admin, Dry Lab / Computational Space
- Rehab, Emergency Department, Biomedical Engineering and Imaging Institute, Artificial Intelligence, and Genetics

Accelerating Innovation and Entrepreneurship: Mount Sinai Innovation Partners

904

Faculty
Engagements

59

Licenses
and Options

305

Research
Contracts

(Providing \$34.7M in funding)

140

Technology
Disclosures

268

New Patent
Applications

(Includes filed provisional, PCT, U.S.,
European, and other foreign national
phase applications and filings)





1,110

Material Transfer
Agreements





311

Confidentiality
Disclosures

Mount Sinai Innovation Partners Spinoffs


	Company Name	Products
	CastleVax	Cell BioEngines is a clinical-stage biotech company focused on developing 'off-the-shelf' allogeneic cell therapies as 'drugs' to turn all cancers into curable diseases.
	Cell BioEngines	Cell BioEngines licensed and is advancing Mount Sinai technologies for the purpose of developing a dendritic cell-based immunotherapy for the treatment of head and neck cancers and a cord blood stem cell treatment for hematologic malignancies.
	LinusBio	Named one of Fierce Biotech's 2024 Fierce 15, LinusBio is developing novel biomarker-based diagnostics and prognostics for the early diagnosis of autism spectrum disorder and ADHD.
	PreciseDX	PreciseDx received New York State Department of Health approval for its advanced AI-enabled breast cancer diagnostic. The company's AI algorithms stratify cancer risk to support precision treatment and care strategies for breast and other cancers.

Mount Sinai Innovation Partners Spinoffs, Cont'd

	Company Name	Products
	GNOMX	Diagnostic tests for infections, specific pathogens, and antibiotic sensitivity.
	Paratus Sciences	Paratus Sciences is committed to improving human health and health security. By advancing the development of licensed Mount Sinai technologies in the field of bat biology, the company aims to develop new therapies in the fields of infectious disease, oncology, metabolism, and aging.
	Renalytix	KDIGO guidelines, FDA, and pending CMS Local Coverage Decision
	Trellus Health	The company's principal product, Trellus Elevate, is a multidisciplinary virtual care support system that surrounds IBD and GI patients with the team and tools to help them manage Crohn's disease, ulcerative colitis, and irritable bowel syndrome. Trellus Health initiated pilot testing of Trellus Elevate with a major health plan in March 2024.

New Treatment — Rejoyn

Dr. Dennis Charney in partnership with Dr. Brian Iacoviello has spearheaded the development of the first prescription digital treatment for major depressive disorder. This innovative treatment, Rejoyn™, has just received approval from the U.S. Food and Drug Administration (FDA). Rejoyn™ incorporates scientifically validated cognitive emotional brain training exercises, such as the Emotional Faces Memory Task, to tackle the complexities of major depressive disorder.



Accelerating Translational Research Through New Research and Educational Initiatives

Institute and Center Directors

- **Michal Elovitz, MD**, Institute for Women's Biomedical Research
- **Sarah Millar, PhD**, Institute for Regenerative Medicine
- **David Muller, MD**, Institute for Equity and Justice in Health Sciences Education
- **Scott Friedman, MD**, Institute for Liver Research
- **Louis Pasquale, MD**, Institute for Eye and Vision Research
- **Alex Manini, MD, MS**, Center for Research on Emerging Substances, Poisoning, Overdoses, and New Discoveries (RESPOND)
- **Panos Roussos, MD, PhD**, Center For Disease Neurogenomics
- **James Tsai, MD**, Center for Ophthalmic Artificial Intelligence and Human Health



New Appointments and Promotions

Chairs



Neil M. Rofsky, MD, MHA

Department of Diagnostic, Molecular and Interventional Radiology



Ana Fernandez-Sesma, PhD

Department of Microbiology



Miriam Merad, MD, PhD

Department of Immunology and Immunotherapy



David C. Thomas, MD, MPHE

Department of Medical Education



Rosalind Wright, MD, MPH

Department of Public Health

Chiefs



Sean Pinney, MD

Cardiology Chief, Mount Sinai Morningside



Michael F. Murray, MD

Chief of the Division of Genomic Medicine



Meena Bansal, MD

Chief of the Division of Liver Diseases

Admin



Lorisa Richards, DNP, MS, RN, FNP, NEA-BC

Acting Chief Nursing Officer, The Mount Sinai Hospital



Jenny Waltzer

Vice President, Oncology and Therapeutic Infusion Services

New Appointments and Promotions

Deans



Yvette Calderon, MD, MS
Equity and Clinical Care



Miriam Merad, MD, PhD
Translation Research
and Therapeutic Innovation



Paul Lawrence, MFA
Scholarly and Research Technologies



Sarah Millar, PhD
Basic Science



**Kimberly Glassman, PhD,
RN, NEA-BC, FAONL, FAAN**
Mount Sinai Phillips School of Nursing



David C. Thomas, MD, MPHE
Medical Education



Rosalind Wright, MD, MPH
Public Health

Senior Associate Deans



Alexis Colvin, MD
Alumni Affairs



Rachel Posner
Research Administration




Carol Gregorio, PhD
Basic Science

Associate Deans



Jack Suben
Design and Resource Management



Lori Jennex
Program for the Protection
of Human Subjects

Department of Public Health



- Establish PhD in Public Health
- Expanding Public Health Masters programs
- Adding courses in climate and health, global health equity, AI and public health, geoinformatics
- Integrating public health across Icahn Mount Sinai research

Rosalind J. Wright, MD, MPH

Dean of Public Health Chair, Department of Public Health

Department of Immunology and Immunotherapy



- Pursuing a comprehensive understanding of the immune system and its impact on human health and disease
- Developing advanced gene and cell engineering technologies to study the immune system
- Exploring how cancer contributes to dysregulation of the immune system
- **Discovery:** Allergy drug can improve lung cancer outcomes

Miriam Merad, MD, PhD

Chair, Department of Immunology and Immunotherapy

Dean, Translation Research and Therapeutic Innovation


Director, Precision Immunology Institute

Opportunities for Career Growth: Investigator Track Faculty

Icahn Mount Sinai's robust faculty development and mentoring programs make us an attractive institution for early-stage and mid-career faculty.

32 New Investigator Track Faculty in:

- AI and Human Health
- Cell Developmental and Regenerative Biology
- Dermatology
- Diagnostic, Molecular, and Interventional Radiology
- Emergency Medicine
- Environmental Medicine and Public Health
- Genetics and Genomic Sciences
- Global Health and Health System Designs
- Immunology and Immunotherapy
- Medicine
- Microbiology
- Neurology
- Neuroscience
- Obstetrics, Gynecology and Reproductive Science
- Oncological Sciences
- Ophthalmology
- Orthopedics
- Otolaryngology
- Pathology, Molecular and Cell-Based Medicine
- Pediatrics
- Pharmacological Sciences
- Psychiatry
- Rehabilitation and Human Performance



Advancing Women in Leadership Roles at Icahn Mount Sinai: Office of Gender Equity in Science and Medicine



Carol R. Horowitz, MD, MPH
Dean



Toni A. Stern, MD, MBA
Senior Associate
Dean



Jenny Lin, MD
Senior Associate
Dean

- **Cultivating leaders**
 - Five new Distinguished Scholars for Junior faculty who are caregivers
 - Two new programs for women faculty: Mid-career and Senior Leadership
- **Advancing equity amongst caregivers**
Gender Equity Action Teams:
 - Promoting Mount Sinai’s family-friendly policies
 - Normalizing those who use their caregiving benefits
 - Tracking gender representation
- **Eliminate gender bias in communications**
 - Project on “Enhancing Mutual Respect”
- **NASEM Action Collaborative**

Amplifying
Equity: A Series
for Advancing
Gender Equity
in *Science &
Medicine*

Center for Stress, Resilience, and Personal Growth (CSRPG)



Deborah B. Marin, MD

Director, Center for Stress, Resilience, and Personal Growth




Jonathan M. DePierro, PhD

Clinical Director, Center for Stress, Resilience, and Personal Growth

- Delivered more than 8,000 confidential behavioral health care visits for employees and their adult co-insured dependents
- 268 workshops and huddles focused on mental health and resilience, including in the EDs, ICUs, and more than 20 GME programs (HRSA-funded)
- Resilience-building Wellness Hub mobile app available to all MSHS faculty and staff
- Work featured in *Resilience: The Science of Mastering Life's Greatest Challenges* (Third ed.) and multiple peer-reviewed articles

Office of Well-Being and Resilience



**Johnathan
A. Ripp,
MD, MPH**

Internal Medicine,
Hospital Medicine



**Lauren
Peccoralo,
MD, MPH**

Internal Medicine,
Primary Care

MENTAL HEALTH AWARENESS

REDuce Grant

- Distributed more than \$400,000 in pilot grant support to mitigate clerical and administrative burden

Response to Faculty Survey

- Mental health resource expansion, leadership/mentorship training, Epic enhancements

Well-Being Champions

- 40+ Faculty Champions, 50+ GME Champions
- 17 departmental plans to address well-being

Residents and Fellows

- Grants to support innovations reducing GME clerical burden/clinical intensity
- Increased mental health and peer support

Medical and Graduate Students, Postdocs

- PEERS program: “Practice, Enhancement, Engagement, Resilience Support”
- Expanded wellness advisors, developed community events, enhanced mental health and crisis support services

Medical Education



ASCEND Curriculum: Fall, 2024

- 18 months: pre-clerkship. 12 months: clerkship. 18 months: post-clerkship
- First in nation: Palliative Medicine clerkship, Chronic Care clerkship
- Dedicated faculty mentor
- Emphasizes student wellness, resiliency, and progressive career and professional development

New Fellowships for MD students

- Leadership in Health care Equity and Administration Scholar Program
- Surgeon Scientist Training Program

David C. Thomas, MD, MS, MHPE

Dean and Chair, Medical Education

Medical Education: Attracting a Diverse Group of the Best and the Brightest Students

	MD/MD-PhD Matriculated 2023	FlexMed Accepted 2023
Number of Matriculating Students	120	41
Self-Identifying as Woman	64 (53%)	22 (54%)
Underrepresented in Medicine/Science	34 (28%)	19 (46%)
Number of Undergraduate Schools	55	23
Median MCAT	517	N/A
Median GPA	3.92	3.97

Excellence in Student Research

- 73 Students graduated with distinction in research
- 147 Students presented at national or international conferences
- 20 students published in high-impact journals



Class of 2024 Match and Graduation

- 133 students matched into 26 specialties
- 50 students entered residency within the Mount Sinai Health System

Graduate School of Biomedical Sciences: Attracting a Diverse Group of the Best and the Brightest Students

2023 PhD Students in Biomedical Sciences and Neuroscience

Size of Class	57
Women	71%
Underrepresented in Science	19%
Median Undergraduate GPA	3.68

Strengths of the Incoming Class of PhD Students

- Students are from 14 different countries
- 37 percent of students have undergraduate degrees in quantitative sciences
- About 200 publications across all students



Recruitment of the largest class for the MSBS program in our history, with 53 new matriculants (20 percent increase over the past five years)

Graduate School of Biomedical Sciences



- Fully integrating AI, Data Science, Computational Biology across curricula
- Partnering with National Science Foundation Innovation Corps
- Offering more than 100 hours training in Biomedical Entrepreneurship
- Expanding Public Health Master's program
- First accredited fellowship program in Health Care Management and Leadership in the United States
- Planning PhD program in Health Sciences Engineering
- Enhancing mentorship

Marta Filizola, PhD

Dean, Graduate School of
Biomedical Sciences

A Leader in Graduate Medical Education

Our graduate medical education program remains the largest in the United States



I. Michael Leitman, MD

Surgery

2023	Female	URM
ISMMS Programs	51%	16%
National Average	42%	11%

2,650
residents and
clinical fellows in
250
GME programs


Program name	No. of Programs in the U.S.	2023 Rank
Occupational Health	23	3
Phys Med/Rehab	107	8
Dermatology	147	10
Psychiatry	300	12
Radiology Diagnostic	200	13
Otolaryngology	130	15
Radiology Nuclear Medicine	37	15
Neurology	178	16
Internal Medicine	622	18
Emergency Medicine	287	19
Anesthesiology	165	19
Obstetrics-Gynecology	301	21
Pathology	147	27
Radiation Oncology	90	27
Internal Medicine/Pediatrics	79	28

Pursuing Reaccreditation From Middle States Commission on Higher Education

- 2.5 year process culminating with submission of a “Self-Study” report, followed by site visit in Spring, 2025.
- Self-Study process: introspective examination of how our educational programming is linked to our institutional mission and strategic goals.
- Steering Committee oversees five Working Groups conducting the Self-Study and will prepare the final report for Middle States.
- Steering Committee and Working Groups are comprised of faculty, administrators, staff, and students with a broad set of backgrounds and expertise.



Office of Diversity, Equity, and Inclusion



Road Map for Action to Address Racism

- Promoting equitable culture
- Training to engage in anti-racism and equitable practices
- Strategic partnerships, policy changes
- Retention and development of under-represented minorities
- Stand against all forms of hate speech
- Anti-Racist Transformation (ART) in Med Ed
- Modeling our Road Map: *Journal of Academic Medicine*
- DEI Summit
- Conference: Transforming Landscape of Medical Education

Gary Butts, PhD

Chief Diversity and Inclusion Officer
Dean for Diversity Programs, Policy,
and Community Affairs

Making Icahn Mount Sinai a More Equitable and Anti-Racist Institution: Road Map for Action



We Stand in Solidarity Against Racism.
And We Are Committed to Equity in Health Care.



Institute for Equity and Justice in Health Sciences Education



**David Muller,
MD**

Director, Institute
for Equity and
Justice in Health
Sciences Education



**Leona Hess,
PhD, MSW**

Co-Director, Institute
for Equity and
Justice in Health
Sciences Education

- Teach health sciences educators to dismantle and disrupt all forms of racism and bias, including Islamophobia and Anti-Semitism
- Oversee the change management strategy to accelerate anti-racist and anti-bias transformation in health sciences education at Icahn Mount Sinai
- Serve as a national resource for best practices and consultation



Institute for Health Equity Research: Reducing Health Disparities and Supporting Health Equity



Carol R. Horowitz, MD, MPH
Director


Lynne D. Richardson, MD
Co-Director

- Influenced U.S. Organ Procurement and Transplantation Network to reform race-based approach that disadvantaged black patients awaiting a transplant
- Developed a community-based intervention to prevent suicide among black youth
- Pioneering AI approaches to uncover and address stigmatizing language in EHRs
- Addressing disparities in mortality for non-English speaking hospital patients
- Supporting deployment of “equity dashboards” to improve quality of clinical care




Mount Sinai Doctors Faculty Practice: Highlights

Ambulatory Volume



Patient Receipt Growth




Mount Sinai Doctors Faculty Practice: Highlights

MyMountSinai

- **1.7M** active users (**16% increase** year over year)
- **25K** activations per month

MyMountSinai Total Users



Digital Bookings

- 22% of all appointments are booked digitally, up from 5% in 2019

Central Billing Office

- Charges \$4.9B (up 10%)
- Cash Collections \$1.2B (up 13%)

What's on the Horizon: Ambulatory Practice



Kelly Cassano, DO

Chief Executive Officer, Mount Sinai
Doctors Faculty Practice

Dean for Clinical Affairs

Senior Vice President for Ambulatory
Operations, Mount Sinai Health System

Expand **MSHS presence** through **organic growth, partnerships, and acquisition** to further **advance** our **tertiary and quaternary** care within the Mount Sinai Health System

Access and Ambulatory Growth



Drive the **clinical enterprise** to further support the **educational and research** mission of the Mount Sinai Health System



Increase market share through continued innovation and unparalleled **access**

- New patient acquisition
- Improved continuity of care and domestic utilization for existing patients
- Optimize existing external relationships
- Establish new external partnerships




Purpose-build a **patient-centered consumer experience** leveraging **technology, access, and ease of use**

Expanding Our Presence in Neighborhoods Where Our Patients Live and Work



158 West 124th Street



373 Park Avenue South



787 11th Avenue



Showcasing Ichan Mount Sinai's Reputation for Research and Academic Excellence



Science
JOURNALS AAAS

- Two new *Science* Supplements in 2023
- Print and digital copies sent to all subscribers
- Podcast segments

What Are Researchers and Clinicians Working on to Improve Cancer Care?

>> For information and to register for this free program, please [click here](#)

92NY



HealthAffairs


- Five *Health Affairs* editorials throughout 2023
- 580,000 monthly readers
- Website banner ads



 The New York Academy of Sciences

- "A.I. in Human Healthcare" two-day symposium

Institutional Advancement: MSHS “Limitless” Capital Campaign Public Phase



\$633.6M
Strategic Programs

\$1.268B
Other Strategic Areas

\$253.2M
Strategic Capital


First Comprehensive Capital Campaign for Health System **\$2.0B**
2017–2025

Raised to Date (as close of 2023) **\$2.05B**
(100% of goal)

Raised in 2023 **\$477.3M**

Ken Davis, MD, a Transformative Leader

Many of these accomplishments would not have been possible without the support of an exceptional human being—Dr. Ken Davis. More than two decades ago, Dr. Davis gave up his research career to become Chief Executive of what was then Mount Sinai Medical Center. He led Mount Sinai out of a financial crisis and made possible the tremendous growth we have experienced. He has been my partner through my many years as Dean of the School of Medicine. Thank you, Ken, for all you've done for Icahn Mount Sinai and the entire Mount Sinai Health System.



Icahn School of Medicine at Mount Sinai: State of the School

Under the leadership of our new Chief Executive Officer, Dr. Brendan Carr, Mount Sinai will achieve new heights of excellence across our three-part mission. Dr. Carr is a renowned expert in emergency medicine and health care policy. He led our emergency department through its epic battle against the COVID-19 pandemic and has also served as a visionary leader in Washington, advocating for essential improvements in the public-private partnership for emergency preparedness.




Mission Statement

The Icahn School of Medicine at Mount Sinai advances science, medicine, and health care delivery for the benefit of humanity through a culture of excellence, innovation, collaboration, and inclusive diversity. We conduct groundbreaking research; educate and nurture the next generation of exceptional clinicians, researchers, teachers, and leaders; and deliver the most advanced compassionate care with an unwavering commitment to health equity.

“It is never
wrong to
do the right
thing.”

MARK TWAIN



Dean Charney's State of the School

I also want to thank all of you for your hard work. Because of you, Icahn Mount Sinai is a bold and innovative school of medicine.

It is thanks to your outstanding clinical care that saves and improves the lives of our patients; your breakthrough research that is unlocking the mysteries of disease and accelerating our progress towards new diagnostics and therapies; your love of teaching; and your dedication to educate the next generation of scientists, physicians, and health professionals. For all these reasons, Icahn Mount Sinai stands among the great medical schools of the world.

I am deeply appreciative of all you do for Icahn Mount Sinai—and for the collaboration and support you give each other, all in the interest of advancing science and medicine for the benefit of humanity.

Thank you!



Thank you

April 2024